Biocryst Pharmaceuticals (BCRX) Net Cash Flow Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -49.94% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -62.71% |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | 36.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.60% |
| Dec 31, 2025 | -29.36% |
| Sep 30, 2025 | 47.95% |
| Jun 30, 2025 | 70.36% |
| Mar 31, 2025 | 26.01% |
| Dec 31, 2024 | -69.57% |
| Sep 30, 2024 | 54.31% |
| Jun 30, 2024 | 29.26% |
| Mar 31, 2024 | 15.75% |
| Dec 31, 2023 | -30.67% |
| Sep 30, 2023 | 27.19% |
| Jun 30, 2023 | -28.41% |
| Mar 31, 2023 | -130.00% |
| Dec 31, 2022 | -11.93% |
| Sep 30, 2022 | -86.77% |
| Jun 30, 2022 | -310.41% |
| Mar 31, 2022 | -142.19% |
| Dec 31, 2021 | 139.69% |
| Sep 30, 2021 | -36.72% |
| Jun 30, 2021 | -6.20% |